Safety of vedolizumab in liver transplant recipients: A systematic review

Research output: Contribution to journalReview articlepeer-review


Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.

Original languageEnglish
Pages (from-to)875-880
JournalUnited European Gastroenterology Journal
Issue number7
Publication statusPublished - Jan 1 2019


  • adverse events
  • inflammatory bowel disease
  • Liver transplantation
  • primary sclerosing cholangitis
  • vedolizumab

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Safety of vedolizumab in liver transplant recipients: A systematic review'. Together they form a unique fingerprint.

Cite this